Remodeling domain interfaces to enhance heterodimer formation

Protein Science

Volumn 6, Issue 4, 1997, Pages 781-788

  Zhu, Zhenping ^a   Presta, Leonard G ^a   Zapata, Gerardo ^a   Carter, Paul ^a  

^a GENENTECH INC   (United States)

Author keywords

bispecific diabody; engineered disulfide bond; knobs into holes

Indexed keywords

AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; DISULFIDE BOND; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; X RAY CRYSTALLOGRAPHY;

EID: 0030909820     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560060404     Document Type: Article

References (27)

1. Bedouelle H, Winter G. 1986. A model of synthetase/transfer RNA interaction as deduced by protein engineering. Nature 320:371-373.
2. Bhat TN, Bentley GA, Fischmann TO, Boulot G, Poljak RJ. 1990. Small rearrangements in structures of Fv and Fab fragments of antibody D1.3 on antigen binding. Nature 347:483-485.
3. Brinkmann U, Reiter Y, Jung S-H, Lee B, Pastan I. 1993. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci USA 90:7538-7542.
4. Carter P. 1991. Mutagenesis facilitated by the removal or introduction of unique restriction sites. In: McPherson MJ, ed. Mutagenesis: A practical approach. Oxford, UK: IRL Press. pp 1-25.
5. Tyr interacts with both subunits. Proc Natl Acad Sci USA 83:1189-1192.
6. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, Wong WLT, Rowland AM, Kotts CE, Carver ME, Yang M, Bourell JH, Shepard HM, Henner D. 1992. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Technology 10:163-167.
7. Carter P, Ridgway J, Zhu Z. 1995. Toward the production of bispecific antibody fragments for clinical applications. J Hematother 4:463-470.
8. HER2 antibody 4D5 and comparison with molecular modelling. J Mol Biol 229:969-995.
9. Fendly BM, Kotts, C, Vetterlein D, Lewis GD, Winget M, Carver ME, Watson SR, Sarup J, Saks S, Ullrich A, Shepard HM. 1990. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J Biol Resp Mod 9:449-455.
10. Holliger P, Prospero T, Winter G. 1993. "Diabodies": Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444-6448.
11. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. 1991. In: Sequences of proteins of immunological interest, 5th edition. Bethesda, MD: National Institutes of Health.
12. Kelley RF, O'Connell MP. 1993. Thermodynamics of an antibody functional epitope. Biochemistry 32:6828-6835.
13. Kunkel TA, Roberts JD, Zakour RA. 1987. Rapid and efficient site-directed mutagenesis without phenotypic selection. Methods Enzymol 154:367-382.
14. McPhee F, Good AC, Kuntz ID, Craik CS. 1996. Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation. Proc Natl Acad Sci USA 93:11477-11481.
15. O'Shea EK, Lumb KJ, Kim PS. 1993. Peptide "velcro": Design of a heterodimeric coiled coil. Curr Biol 3:658-667.
16. Ponder J, Richards F. 1987. Use of packing criteria in the enumeration of allowed sequences for different structural classes. J Mol Biol 194:775-791.
17. Reiter Y, Brinkmann U, Kreitman RJ, Jung S-H, Lee B, Pastan I. 1994a. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry 33:5451-5459.
18. Reiter Y, Brinkmann U, Webber KO, Jung SH, Lee B, Pastan I. 1994b. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: Improved biochemical characteristics of recombinant immunotoxins containing disulfide-linked Fv. Protein Eng 7:697-704.
19. H3 domains for heavy chain heterodimerization. Protein Eng 9:617-621.
20. Robey EA, Schachman HK. 1985. Regeneration of active enzyme by formation of hybrids from inactive derivatives: Implications for active sites shared between polypeptide chains of aspartate transcarbamoylase. Proc Natl Acad Sci USA 82:361-365.
21. 2 fragment for improved binding to T cells. Intl J Cancer (Suppl) 7:45-50.
22. HER2 Fv-β-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res 55:63-70.
23. Ward WHJ, Jones DH, Fersht AR. 1987. Effects of engineering complementary charged residues into the hydrophobic subunit interface of tyrosyl-tRNA synthetase. Biochemistry 26:4131-4138.
24. Wente SR, Schachman HK. 1987. Shared active sites in oligomeric enzymes: Model studies with defective mutants of aspartate transcarboylase produced by site-directed mutagenesis. Proc Natl Acad Sci USA 84:31-35.
25. 2 fragments for efficient production in Escherichia coli and enhanced anti-proliferative activity. Protein Eng 8:1057-1062.
26. Zhu Z, Carter P. 1995. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. J Immunol 155:1903-1910.
27. Zhu Z, Zapata G, Shalaby MR, Snedecor B, Chen H, Carter P. 1996. High level secretion of a humanized bispecific diabody from Escherichia coli. Bio/ Technology 14:192-196.